2023
Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis
Luukkonen P, Sakuma I, Gaspar R, Mooring M, Nasiri A, Kahn M, Zhang X, Zhang D, Sammalkorpi H, Penttilä A, Orho-Melander M, Arola J, Juuti A, Zhang X, Yimlamai D, Yki-Järvinen H, Petersen K, Shulman G. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2217543120. PMID: 36669104, PMCID: PMC9942818, DOI: 10.1073/pnas.2217543120.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseLiver fibrosisLiver diseaseCommon chronic liver diseaseChronic liver diseaseFatty liver diseaseRisk of fibrosisDistinct mouse modelsPyrimidine catabolismNonalcoholic steatohepatitisMouse modelTherapeutic targetFibrosisDihydropyrimidine dehydrogenaseHuman liverA variantCommon variantsMetabolomics approachDiseaseMiceInhibitionCatabolismKnockdownSteatohepatitisGimeracil
2006
Toll-like receptor 4 deficiency causes pulmonary emphysema
Zhang X, Shan P, Jiang G, Cohn L, Lee PJ. Toll-like receptor 4 deficiency causes pulmonary emphysema. Journal Of Clinical Investigation 2006, 116: 3050-3059. PMID: 17053835, PMCID: PMC1616193, DOI: 10.1172/jci28139.Peer-Reviewed Original ResearchConceptsToll-like receptor 4 deficiencyEndothelial cellsOxidant generationLung structural cellsAdoptive transfer experimentsNormal lung architectureDevelopment of emphysemaTLR4 deficiencyTLR4 expressionAirspace enlargementLung diseaseLung architecturePulmonary emphysemaLung integrityCigarette smokeLung elasticityEmphysemaNADPH inhibitorStructural cellsLungNovel NADPH oxidaseNADPH oxidaseElastolytic activityTLRMice